Table 3.
Clinical significance of neostigmine for ACPO.
| Author | Experimental group |
Control group |
||||||
|---|---|---|---|---|---|---|---|---|
| Year | Event | Total | Event | Total | NNT | 95% CI | ||
| Clinical response | ||||||||
| Orlando | 1994 | 17 | 20 | 9 | 20 | 3 | 1 | 8 |
| Ponec | 1999 | 10 | 11 | 0 | 10 | 1 | 1 | 2 |
| von der Spoel | 2001 | 11 | 13 | 0 | 11 | 1 | 1 | 2 |
| Fanaei | 2008 | 20 | 21 | 0 | 21 | 2 | 1 | 2 |
| Total | 58 | 65 | 9 | 62 | 1 | 1 | 2 | |
| Abdominal pain | ||||||||
| Ponec | 1999 | 8 | 11 | 0 | 10 | 1 | 1 | 2 |
| Fanaei | 2008 | 9 | 21 | 0 | 21 | 2 | 2 | 5 |
| Total | 17 | 32 | 0 | 31 | 2 | 1 | 3 | |
| Sialorrhoea | ||||||||
| Ponec | 1999 | 3 | 11 | 0 | 10 | 4 | 2 | 12 |
| von der Spoel | 2001 | 3 | 13 | 0 | 11 | 5 | 2 | 22 |
| Fanaei | 2008 | 8 | 21 | 0 | 21 | 3 | 2 | 8 |
| Total | 14 | 45 | 0 | 62 | 3 | 2 | 6 | |
| Vomiting | ||||||||
| Ponec | 1999 | 1 | 11 | 0 | 10 | 13 | 3 | 5 |
| Fanaei | 2008 | 4 | 21 | 0 | 21 | 6 | 3 | 54 |
| Total | 5 | 32 | 0 | 31 | 7 | 3 | 375 | |
| Bradycardia | ||||||||
| Ponec | 1999 | 1 | 11 | 0 | 10 | 13 | 3 | 5 |
| Fanaei | 2008 | 1 | 21 | 0 | 21 | 23 | 4 | 9 |
| Total | 2 | 32 | 0 | 31 | 16 | 6 | 25 | |
NNT=Number needed to treat; NNH=Number needed to harm.